In the current study, investigation of the HDAC inhibitor SAHA demonstrated its potential as a secondary treatment to improve the effects of azole treatment against both biofilm and planktonic states of Aspergillus spp. This activity appears to occur largely via the inhibition of HSP90. Future in vivo studies as well as studies focusing on underlying mechanisms will be beneficial to understand the clinical use of these combinations against Aspergillus-associated infections. Here, HDAC9 is linked to infection.